| Pharmacogenetics of opioids AA Somogyi, DT Barratt, JK Coller Clinical Pharmacology & Therapeutics 81 (3), 429-444, 2007 | 415 | 2007 |
| MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy S Elad, KKF Cheng, RV Lalla, N Yarom, C Hong, RM Logan, J Bowen, ... Cancer 126 (19), 4423-4431, 2020 | 410 | 2020 |
| Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence JK Coller, MR Hutchinson Pharmacology & therapeutics 134 (2), 219-245, 2012 | 198 | 2012 |
| The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver JK Coller, N Krebsfaenger, K Klein, K Endrizzi, R Wolbold, T Lang, ... British journal of clinical pharmacology 54 (2), 157-167, 2002 | 172 | 2002 |
| ABCB1 genetic variability and methadone dosage requirements in opioid‐dependent individuals JK Coller, DT Barratt, K Dahlen, MH Loennechen, AA Somogyi Clinical Pharmacology & Therapeutics 80 (6), 682-690, 2006 | 165 | 2006 |
| CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes MR Hutchinson, A Menelaou, DJR Foster, JK Coller, AA Somogyi British journal of clinical pharmacology 57 (3), 287-297, 2004 | 150 | 2004 |
| Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms HR Wardill, RJ Gibson, YZA Van Sebille, KR Secombe, JK Coller, ... Molecular cancer therapeutics 15 (6), 1376-1386, 2016 | 149 | 2016 |
| Role of active metabolites in the use of opioids JK Coller, LL Christrup, AA Somogyi European journal of clinical pharmacology 65, 121-139, 2009 | 136 | 2009 |
| Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment Y Wu, EL Lousberg, LM Moldenhauer, JD Hayball, SA Robertson, ... Brain, behavior, and immunity 25, S155-S164, 2011 | 87 | 2011 |
| Inhibiting the TLR4‐MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol‐induced sedation and motor impairment in mice Y Wu, EL Lousberg, LM Moldenhauer, JD Hayball, JK Coller, KC Rice, ... British journal of pharmacology 165 (5), 1319-1329, 2012 | 80 | 2012 |
| Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strains L Liu, JK Coller, LR Watkins, AA Somogyi, MR Hutchinson Brain, behavior, and immunity 25 (6), 1223-1232, 2011 | 72 | 2011 |
| Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines JM Bowen, RJ Gibson, JK Coller, N Blijlevens, P Bossi, N Al-Dasooqi, ... Supportive Care in Cancer 27, 4011-4022, 2019 | 69 | 2019 |
| The bidirectional interaction of the gut microbiome and the innate immune system: Implications for chemotherapy‐induced gastrointestinal toxicity KR Secombe, JK Coller, RJ Gibson, HR Wardill, JM Bowen International journal of cancer 144 (10), 2365-2376, 2019 | 67 | 2019 |
| CYP2B6*6 allele and age substantially reduce steady‐state ketamine clearance in chronic pain patients: impact on adverse effects Y Li, KA Jackson, B Slon, JR Hardy, M Franco, L William, P Poon, ... British journal of clinical pharmacology 80 (2), 276-284, 2015 | 67 | 2015 |
| Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours JK Coller, P Fritz, UM Zanger, I Siegle, M Eichelbaum, HK Kroemer, ... The histochemical journal 33, 329-336, 2001 | 64 | 2001 |
| Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments DT Barratt, JK Coller, AA Somogyi American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 141 …, 2006 | 63 | 2006 |
| The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation NA Helsby, CY Hui, MA Goldthorpe, JK Coller, MC Soh, PJ Gow, ... British journal of clinical pharmacology 70 (6), 844-853, 2010 | 60 | 2010 |
| ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics DT Barratt, JK Coller, R Hallinan, A Byrne, JM White, DJR Foster, ... Pharmacogenomics and personalized medicine, 53-62, 2012 | 59 | 2012 |
| Comparison of (S)‐mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms Coller, Somogyi, Bochner British journal of clinical pharmacology 48 (2), 158-167, 1999 | 57 | 1999 |
| OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence JK Coller, S Cahill, C Edmonds, AL Farquharson, M Longo, R Minniti, ... Pharmacogenetics and genomics 21 (12), 902-905, 2011 | 51 | 2011 |
